781 results on '"Sokol, Lubomir"'
Search Results
2. The CNS relapse in T-cell lymphoma index predicts CNS relapse in patients with T- and NK-cell lymphomas
3. Effective treatment with the selective cytokine inhibitor BNZ-1 reveals the cytokine dependency of T-LGL leukemia
4. Sézary syndrome originates from heavily mutated hematopoietic progenitors
5. Multicenter phase 2 study of oral azacitidine (CC-486) plus CHOP as initial treatment for PTCL
6. Brentuximab vedotin plus doxorubicin and dacarbazine in nonbulky limited-stage classical Hodgkin lymphoma
7. Tγδ LGLL identifies a subset with more symptomatic disease: analysis of an international cohort of 137 patients
8. B‐cell maturation antigen expression and clinical features of plasmablastic lymphoma
9. Bendamustine and rituximab as frontline therapy in extranodal marginal zone lymphoma: a single-institution experience
10. Survival outcomes in blastic plasmacytoid dendritic cell neoplasm by first-line treatment and stem cell transplant
11. Non-del(5q) myelodysplastic syndromes–associated loci detected by SNP-array genome-wide association meta-analysis
12. Oral 5-azacytidine and romidepsin exhibit marked activity in patients with PTCL: a multicenter phase 1 study
13. Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015.
14. Hematological Malignancies and Arterial Thromboembolism
15. Brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine for nonbulky limited-stage classical Hodgkin lymphoma
16. Primary Effusion Lymphoma: Small Bowel Recurrence After Stem Cell Transplant
17. Non-Hodgkin's lymphomas, version 4.2014.
18. Phase I evaluation of XL019, an oral, potent, and selective JAK2 inhibitor
19. Mycosis Fungoides Masquerading as Acrodermatitis Continua of Hallopeau
20. Clinical Practice Recommendations on Indication and Timing of Hematopoietic Cell Transplantation in Mature T Cell and NK/T Cell Lymphomas: An International Collaborative Effort on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation
21. Insights into the Impact of Hesitancy on Cancer Care and COVID-19
22. Abstract 744: Treatment inequities among patients diagnosed with Hodgkin's lymphoma with and without HIV (2018-2019): an analysis of the US National Cancer Database
23. Delineation of clinical course, outcomes, and prognostic factors in patients with T‐cell prolymphocytic leukemia
24. The role of anti-PD-1 and anti-PD-L1 agents in the treatment of diffuse large B-cell lymphoma: The future is now
25. The NLRP3 inflammasome functions as a driver of the myelodysplastic syndrome phenotype
26. Severe Thrombocytopenia in a Patient With a History of Olfactory Neuroblastoma
27. Methyltransferase inhibitors restore SATB1 protective activity against cutaneous T cell lymphoma in mice
28. Phase 1/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma
29. Mogamulizumab-Associated Rash (MAR) Correlates with Longer Progression Free Survival in Cutaneous T Cell Lymphoma (CTCL)
30. Autologous Hematopoietic Cell Transplant Consolidation for First Response Is Associated with Longer Survival in Patients with Nodal Peripheral T-Cell Lymphoma
31. Comparing Survival Outcomes of Autologous and Allogeneic Hematopoietic Cell Transplantation in Patients with Relapsed/Refractory Nodal Peripheral T-Cell Lymphoma
32. Efficacy of Combinatorial Treatment Approaches in CTCL
33. CNS Relapse in T-Cell Lymphoma Index: A Risk Score to Predict Central Nervous System Relapse in Patients with T-Cell Lymphomas
34. Rosai–Dorfman Disease between Proliferation and Neoplasia
35. Tγδ LGL LEUKEMIA IDENTIFIES A SUBSET WITH MORE SYMPTOMATIC DISEASE: ANALYSIS OF AN INTERNATIONAL COHORT OF 137 PATIENTS
36. TP53 suppression promotes erythropoiesis in del(5q) MDS, suggesting a targeted therapeutic strategy in lenalidomide-resistant patients
37. Clinical Insights into the Management of Blastic Plasmacytoid Dendritic Cell Neoplasm
38. 'Alterations in the Skin Microbiota Are Associated With Symptom Severity in Mycosis Fungoides'
39. miR-21 mediates hematopoietic suppression in MDS by activating TGF-β signaling
40. A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide
41. A Critical Role for Phosphatase Haplodeficiency in the Selective Suppression of Deletion 5q MDS by Lenalidomide
42. High Rates of Remission with the Initial Treatment of Oral Azacitidine Plus CHOP for Peripheral T-Cell Lymphoma (PTCL): Clinical Outcomes and Biomarker Analysis of a Multi-Center Phase II Study
43. Final Results from a Phase 2 Study of Tipifarnib in Subjects with Relapsed or Refractory Peripheral T-Cell Lymphoma
44. Two Distinct Clinical Courses and Outcomes in T-Cell Prolymphocytic Leukemia
45. Upfront Targeted Tyrosine Kinase Inhibitor Therapy Improves Outcome in Patients with Myeloid/Lymphoid Neoplasms with Eosinophilia
46. Lymphocyte Recovery Following Autologous Hematopoietic Stem Cell Transplant in Classical Hodgkin Lymphoma
47. Clinical Features and Treatment Outcomes of Large Granular Lymphocytic Leukemia Coexisting with Autoimmune Diseases
48. A Multi-Institutional Retrospective Analysis of T-Cell Lymphomas with Central Nervous System Relapse
49. A Single-Arm, Open-Label Phase 2 Pilot Study of Vyxeos (CPX-351) in Adults with Relapsed or Refractory Acute Lymphoblastic Leukemia
50. Updates from Ongoing, First-in-Human Phase 1 Dose Escalation and Expansion Study of TTI-621, a Novel Biologic Targeting CD47, in Patients with Relapsed or Refractory Hematologic Malignancies
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.